TheEdgeResearch
Home / Stocks / ISCNF

Isracann Biosciences Inc. (ISCNF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$1,760
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.19
52-Wk Range
0.000001-0.00021
CEO
Ajay Singh Kaila
Country
CA
Currency
USD

Isracann Biosciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,760. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of 0.0%. Its beta of 0.19 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.47
Price / Sales
0.00
Price / Book
7.55
EV / EBITDA
-0.97
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
0.38
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2017-12-15
Headquarters
Vancouver, BC, CA
About Isracann Biosciences Inc.

Founded in 2010 and based in Vancouver, Canada, Isracann Biosciences Inc. focuses on the cultivation and distribution of medical cannabis. The company conducts its operations and develops its growing infrastructure within Israel, also serving the German market through product exports. Its current name, Isracann Biosciences Inc., was adopted in October 2019, succeeding its former identity as Atlas Blockchain Group Inc.

Comparable companies

Isracann Biosciences Inc. is most often compared with the following Healthcare names:

AVCNFCAAOFCHOOFCWBHFEVRRFGBLPMEDIFMRESRAPHVYYRF
More research on ISCNF
ISCNF technical analysis ISCNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →